Compare AbbVie Inc (ABBV) vs JPMorgan Equity Premium Income ETF (JEPI) Price & Performance

AbbVie IncTrade

JPMorgan Equity Premium Income ETFTrade

Price performance (Past 24H)

Key statistics

AbbVie Inc vs JPMorgan Equity Premium Income ETF — how do they compare? AbbVie Inc trades at $249.78 (market cap $441.94B), while JPMorgan Equity Premium Income ETF trades at $57.82. The key difference: AbbVie Inc pays a 2.77% dividend while JPMorgan Equity Premium Income ETF pays none, and AbbVie Inc is trading nearer its 52-week high, JPMorgan Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.

	ABBV	JEPI
Market Cap	$441.94B	—
Sector	Health	Income / Options Overlay
52-Week High	$263.58	$59.88
52-Week Low	$197.38	$55.29
Enterprise Value	$506.19B	—
Dividend Yield	2.77%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbbVie Inc

AbbVie (ABBV) trades at $247.91, up 0.76% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 70.73% buy consensus highlight robust fundamentals, driven by Skyrizi and Rinvoq growth offsetting Humira declines. Positive news includes Phase 2 ovarian cancer data and institutional stake increases, reinforcing momentum.

Outlook remains positive with a $278.69 price target, though risks include patent cliffs and debt levels. Revenue growth and dividend stability offer appeal, but investors should monitor competitive pressures and regulatory developments for sustained performance.

JPMorgan Equity Premium Income ETF

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

ABBV

Fidelity Dividend ETF's payout is safe but not ideal for steady income due to variable quarterly dividends.24/7 Wall Street · 23 hours agoNeutral Two Dividend Aristocrats outperformed the market while two lagged; three new picks show promising dividend growth.24/7 Wall Street · 2 days agoNeutral Healthcare sector leads S&P 500 gains over 3 months with key pharma stocks showing strong innovation and income potential.24/7 Wall Street · 2 days agoBullish View details →

JEPI

SPYI ETF offers high tax-free yield but with high fees and capped upside in Roth IRAs.24/7 Wall Street · 18 hours agoBearish Eaton Vance EVT offers tax-efficient monthly income vs JPMorgan JEPI's ordinary income hit.24/7 Wall Street · 21 hours agoBullish JPMorgan Equity Premium Income ETF lags peers with lowest yield, prompting cautious stance from investors.Seeking Alpha · 2 days agoNeutral View details →

About AbbVie Inc

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

About JPMorgan Equity Premium Income ETF

JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.